Biomind Labs Inc. (CVE:BMND.NE) | WebDisclosure

Basculer en Français

10965	Companies
240137	Keywords
168910	Articles
129233	Press releases

Home
Companies
Biomind Labs Inc.

PRESS RELEASE

published on 11/21/2024 at 00:25, 1 year 9 months ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Biomind Labs Inc., a leading biotech company, optimistic about U.S. government's stance on psychedelic industry. Company's BMND08 shows promising results in Phase II trial for neuropsychiatric disorders

FDA Neuropsychiatric Disorders Biomind Labs Inc. BMND08 Psychedelic Industry
BRIEF

published on 07/18/2024 at 14:35, 2 years 1 month ago

Biomind Labs Advances New Obesity Treatment with BMND06 Candidate Targeting Neurological Pathways

Obesity Treatment Clinical Trial Biomind Labs BMND06 Anti-inflammatory
BRIEF

published on 07/18/2024 at 14:35, 2 years 1 month ago

Biomind Labs fait progresser un nouveau traitement contre l'obésité avec le candidat BMND06 ciblant les voies neurologiques

Essai Clinique Traitement De L'obésité BMND06 Laboratoires Bioesprit Anti-inflammatoire
PRESS RELEASE

published on 07/18/2024 at 14:30, 2 years 1 month ago

Biomind Labs To Redefine Obesity Treatment With Its New BMND06 Candidate Targeting Neurological Pathways
Biomind Labs announced the decision to advance a Phase II clinical trial for BMND06, a novel compound with potential anti-inflammatory properties for treating obesity and neurological disorders

Phase II Trial Obesity Biomind Labs BMND06 Anti-inflammatory

Accesswire

Published on 09/12/2026 at 02:35, 11 hours 1 minute ago

Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 14 hours 36 minutes ago

Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 31 minutes ago

Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 11 minutes ago

Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 20 hours 36 minutes ago

Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors

View all ACCESSWIRE

EQS Group

Published on 09/12/2026 at 07:30, 6 hours 6 minutes ago

NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 21 minutes ago

Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 26 minutes ago

Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 17 hours 51 minutes ago

DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 21 minutes ago

CGTN: How BRICS creates new opportunities for Global South development

Les Echos

Published on 09/11/2026 at 07:00, 1 day 6 hours ago

Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 1 day 6 hours ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 1 day 6 hours ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 6 hours ago

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago

Availability of the 2026 Interim Financial Report

View all LES ECHOS COMFI WIRE